BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that Appleton Medical Services, Inc. (Appleton) has purchased an additional MicroThermX® Microwave Ablation System (MicroThermX®). Appleton purchased the additional MicroThermX® for use in key institutions within their distribution area. Appleton has been BSD's distributor of the MicroThermX® product line since May 2011, and continues to purchase an increasing number of SynchroWave disposable antennas. Appleton's purchase of an additional generator reflects the growth of the market for the Company's ablation products, as well as BSD's strengthening relationship with Appleton.
Appleton is a leading seller of state-of-the-art, minimally invasive, surgical products and has a 34-year history of selling specialty surgical devices produced by some of the leading medical companies in the U.S. Appleton has a dedicated team of veteran sales personnel who specialize in selling a select group of surgical products targeted for the interventional radiology market. Appleton, working in conjunction with BSD's direct sales representatives, markets the MicroThermX® line of products in the states of Missouri, Louisiana, Oklahoma, Mississippi, Arkansas, Kansas, Iowa, Nebraska and Texas.
About the MicroThermX® Microwave Ablation System
The MicroThermX® Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® system in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets, and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.